Browse the evidence

GIP has pleiotropic effects beyond glucose metabolism, including potential benefits for obesity, bone health, and neurodegenerative disorders, making it a candidate for pharmacotherapies.

GIP is not just a blood sugar hormone. It also influences fat storage, bone density, and brain health. This is why new drugs that mimic or modify GIP are being studied for obesity and even neurodegenerative diseases.

Targeting specific inflammatory pathways (IL-1beta, NLRP3) reduces cardiovascular disease events in patients with obesity and elevated inflammation, independent of lipid-lowering effects.

If you have obesity and high inflammation markers (like CRP), your risk of heart disease is significantly driven by inflammation, not just cholesterol. While lifestyle changes are primary, emerging treatments targeting inflammation (like IL-1beta blockers) can reduce heart events by ~15% in high-risk groups, though they carry infection risks and do not fix blood sugar issues.

In high-risk type 2 diabetes patients, higher BMI and waist circumference are significantly associated with worse cardiometabolic control (higher triglycerides, lower HDL-C, higher blood pressure) and higher medication intensity, despite these patients receiving more aggressive lipid and blood pressure therapy.

For patients with T2DM and high heart risk, carrying excess weight (high BMI or waist circumference) is strongly linked to harder-to-control blood pressure, cholesterol, and blood sugar, even when doctors prescribe more medication. Addressing adiposity is critical because it correlates with better control of these major risk factors.

GLP-1 receptor agonists (specifically liraglutide) reduce cardiovascular events by preventing the progression of atherosclerosis, whereas SGLT2 inhibitors (empagliflozin) reduce mortality linked to cardiovascular events likely through hemodynamic and volume depletion effects rather than atherosclerosis modulation.

Understand that while both empagliflozin and liraglutide protect the heart, they may do so differently. Empagliflozin works quickly to reduce fluid load and heart stress (beneficial for heart failure), while liraglutide may work more slowly to protect blood vessels from plaque buildup. This distinction helps doctors choose the right drug for your specific heart condition.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces systolic and diastolic blood pressure in patients with type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, tirzepatide (a once-weekly injection) can help lower your blood pressure, which reduces your overall cardiovascular risk. The blood pressure reduction is dose-dependent, meaning higher doses tend to lower BP more.

Tirzepatide reduces inflammatory markers associated with cardiovascular risk, including YKL-40, ICAM-1, leptin, and GDF-15.

Tirzepatide reduces inflammatory markers associated with cardiovascular risk, such as YKL-40, ICAM-1, leptin, and GDF-15. This reduction in inflammation may contribute to the overall cardiovascular benefits of the drug.

Caloric restriction (25% deficit) improves metabolic flexibility, evidenced by amplified fasting-to-postprandial differences in acylcarnitines and free fatty acids, which correlates with improved insulin sensitivity.

To improve metabolic flexibility, consider a sustained caloric restriction of about 25% below your maintenance needs. This approach helps your body better switch between burning fat and glucose, which is linked to better insulin sensitivity. This is most effective if you are currently sedentary and have a normal-to-overweight BMI.

Higher cardiorespiratory fitness (CRF) causally reduces the risk of type 2 diabetes, independent of adiposity (BMI), with a 1-SD increase in genetically predicted fitness associated with an 11% lower risk.

Improving your cardiorespiratory fitness (VO2max) directly lowers your risk of type 2 diabetes, regardless of your weight. Focus on exercises that challenge your heart and lungs (like cycling or running) to improve your body's ability to use oxygen, as this has independent metabolic benefits beyond just burning calories.

Visceral obesity and metabolic syndrome increase the risk of esophageal adenocarcinoma (EAC) through both GERD-dependent mechanisms (increased acid exposure) and GERD-independent mechanisms (systemic inflammation, adipokine signaling, and microbiome alterations).

Maintain a healthy waist circumference and manage metabolic health markers (blood pressure, blood sugar, lipids) to reduce the risk of esophageal adenocarcinoma. This involves addressing visceral fat through diet and exercise, as it impacts cancer risk through both acid reflux and systemic inflammation.

Baseline levels of fibroblast growth factor 21 (FGF-21) significantly predict the magnitude of weight loss during the first three months of dietary intervention, whereas other inflammatory and cardiovascular biomarkers do not.

Current blood tests for inflammatory or cardiovascular proteins cannot tell you which diet (low-fat or low-carb) will work best for you. The only protein that showed predictive power for weight loss magnitude was FGF-21, but even that has limited utility for individualized advice. Focus on adherence to a sustainable dietary pattern rather than seeking a predictive blood test.

Weight loss interventions lead to significant changes in the plasma levels of 130 inflammatory and cardiovascular proteins, with most decreasing alongside BMI reduction.

Losing weight significantly alters your body's inflammatory and cardiovascular protein profile. This confirms that weight loss has systemic biological benefits beyond just size reduction, improving metabolic health markers.

Semaglutide therapy significantly reduces systemic inflammation, as measured by C-reactive protein (CRP) levels, compared to placebo or other glucose-lowering drugs, regardless of whether the patient has type 2 diabetes or obesity without diabetes.

If you are taking semaglutide for diabetes or weight management, you can expect it to lower your systemic inflammation (measured by CRP). This benefit occurs whether you take the pill or the injection, and whether or not you have diabetes. This anti-inflammatory effect is likely a key reason why semaglutide reduces heart disease risk.

Protein hydrolysates may induce a more potent insulinotropic effect (higher insulin response) than intact proteins, although this does not necessarily translate to greater muscle protein synthesis.

Hydrolysates might spike your insulin more than regular protein, but this doesn't mean you build more muscle. Insulin helps inhibit muscle breakdown, but since MPS is the same, the extra insulin spike is likely unnecessary for most people.

High molecular weight (HMW) adiponectin levels are inversely associated with insulin resistance (HOMA-IR), and this protective relationship is significantly stronger in Aboriginal, Chinese, and South Asian populations compared to European populations.

If you are of Aboriginal, Chinese, or South Asian descent, your body's sensitivity to HMW adiponectin—a hormone that improves insulin sensitivity—may differ from Europeans. Specifically, lower levels of this hormone may have a more pronounced negative impact on your insulin resistance. While you cannot change your ethnicity, focusing on maintaining healthy visceral fat levels through diet and exercise is critical, as adiponectin levels are inversely related to adiposity.

GLP-1 analog treatment (semaglutide and liraglutide) reduces short-term appetite, decreases energy intake, and lowers preference for energy-dense foods (high-fat, sweet, and salty) during the weight loss phase, primarily through mechanisms involving delayed gastric emptying and interaction with brain reward pathways.

GLP-1 medications like semaglutide and liraglutide reduce hunger and change food preferences, particularly reducing cravings for high-fat and sweet foods, during the initial 12-18 months of treatment. This leads to significant weight loss (up to 15%). Side effects like nausea are common but can be managed by starting with lower doses and increasing slowly.

Transdermal estrogen therapy (100 µg/day) combined with 12 weeks of progressive resistance training significantly amplifies skeletal muscle mass gains (quadriceps cross-sectional area and whole-body fat-free mass) in early postmenopausal women compared to resistance training with placebo.

If you are an early postmenopausal woman struggling to build muscle despite consistent resistance training, discuss transdermal estrogen therapy with your doctor. This study suggests that adding 100 µg/day of transdermal estradiol to your routine can nearly double your muscle mass gains compared to training alone. This is not a magic bullet but a hormonal optimization that may be particularly relevant if you are in the first 5 years post-menopause.

GLP-1 receptor agonists improve liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing liver fat content, liver stiffness, and liver enzymes (ALT, AST).

If you have fatty liver disease (MASLD) along with diabetes or obesity, GLP-1 medications can help reduce fat in your liver, lower liver enzymes, and improve liver stiffness, potentially slowing or reversing liver damage.

Among GLP-1RAs, Dulaglutide has the lowest risk of causing intolerable gastrointestinal adverse reactions, while Semaglutide and Liraglutide have the highest risk.

If you are experiencing intolerable gastrointestinal side effects on one GLP-1RA (like Semaglutide or Liraglutide), switching to Dulaglutide may reduce these side effects, as it has the lowest risk of intolerable GI reactions among the studied agents.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss and glycemic control, often superior to other GLP-1 agents.

Tirzepatide is a once-weekly injection that helps with weight loss and blood sugar. It works by targeting two hormones. Higher doses lead to more weight loss. It is an option if other GLP-1 drugs are not enough.

Fixed-ratio combinations of GLP-1 receptor agonists and basal insulin provide superior glycemic control and weight loss compared to insulin alone, without increasing hypoglycemia risk.

If you need insulin for diabetes, adding a GLP-1 drug might help you control your blood sugar better without gaining weight. It's a single injection that combines both medications.

Real-world users of semaglutide (Wegovy) for weight management rarely follow recommended dose titration protocols, with the majority stopping at or below 1.0 mg rather than reaching the target 2.4 mg dose evaluated in clinical trials.

If you are using Wegovy, know that most people do not reach the maximum 2.4 mg dose. Many stop at 1.0 mg due to side effects or cost. This does not mean the drug isn't working for you, but it may mean your weight loss potential is lower than what is seen in clinical trials. Discuss your dose with your provider to see if escalation is appropriate for your tolerance and financial situation.

In adults with prediabetes, women experience less sustained weight loss and greater loss of fat-free mass and bone mineral content compared to men during long-term lifestyle interventions, despite showing greater improvements in some cardiometabolic markers like fasting glucose and HDL.

Women in this study lost less weight and more muscle/bone than men following the same lifestyle program. To mitigate this, women should prioritize resistance training and protein intake to protect lean mass, and focus on metabolic improvements (like blood sugar and cholesterol) rather than just scale weight, as these may improve even if weight loss is modest.

Low-volume high-intensity interval training (LV-HIT) significantly reduces circulating miRNA-27b expression in women with polycystic ovary syndrome (PCOS), whereas high-volume HIT (HV-HIT) does not, despite both improving cardiorespiratory fitness.

For women with PCOS, low-volume high-intensity interval training (10 one-minute maximal efforts with rest) is effective at reducing circulating miRNA-27b levels, a marker linked to metabolism and inflammation. Interestingly, a higher-volume protocol (4x4 minutes) improved fitness but did not change this specific marker, suggesting that training volume and structure matter for molecular adaptations even when fitness gains are similar.

Women tend to lose more weight than men when treated with GLP-1 receptor agonists (semaglutide, liraglutide) for obesity, despite men often losing more weight with lifestyle interventions alone.

If you are a woman being treated with GLP-1 medications like Wegovy or Saxenda, you are statistically likely to lose more weight than a man on the same drug. This is due to how your body processes the medication. Do not compare your progress to male baselines or lifestyle-only results; your pharmacological response is typically superior.